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ABSTRACT 
The standardized uptake value (SUV) is increasingly being used for 
diagnosis, staging , and monitoring disease in clinical oncology. Comparing tumor 
SUV to background SUV is an attractive way to minimize variability and ensure 
the quality of scans across different institutions. The liver has been identified as a 
potential source for background normalization , however no studies have 
compared the liver to other background sites for a variety of cancers. The 
purpose of this study was to evaluate the use of liver uptake for the 
standardization of FOG PET/CT imaging. Scans from 145 patients were 
prospectively reviewed under the supervision of a radiologist with board 
certification in nuclear medicine (R.M.S. , 3 years of experience). Liver SUV 
values were correlated to mediastinum SUV values in lung and breast cancer 
patients, and internal jugular vein (IJV) SUV values in head and neck cancer 
patients. The independent t-test was used to determine if there was a statistically 
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significant affect of the amount of incubation time or use of intravenous contrast 
on the SUV. For the lung and breast cancer patients, a strong correlation was 
observed between the mediastinum SUVmean and liver SUVmean (r = 0.89), 
whereas for the head and neck cancer patients, a weaker correlation was 
observed between the IJV SUVmean and the liver SUVmean (r = 0.69) . Neither the 
amount of incubation time nor the use of IV contrast demonstrated a significant 
affect on the SUV. We conclude that liver SUVmean may be used to standardize 
FOG PET/CT studies in cancers of the lung, breast and head and neck. 
However, additional studies in other cancers as well as the affects of age, 
gender, benign disease and use of chemotherapy are still desired before 
widespread adoption of this standard. 
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Introduction 
Fluorodeoxyglucose- Positron Emission Tomography/ Computed 
Tomography (FDG-PET/CT) has emerged as a valuable diagnostic tool in clinical 
oncology 1. The technique combines functional and anatomic imaging modalities 
to spatially and temporally localize regions of increased glucose utilization. 
Historically, qualitative visual inspection of PET/CT images has been used for 
image interpretation. However, the value of PET/CT as a quantitative tool 
continues to be demonstrated through research . Studies have shown that 
PET/CT provides a more accurate and less observer-dependent measure for 
prognosis and response monitoring purposes than visual inspection alone2 . As 
quantitative approaches to analysis continue to gain acceptance, quantitative 
FDG-PET/CT is being increasingly used in the diagnosis, staging and restaging 
of a number of malignancies3-5 . 
The standardized uptake value (SUV) is a commonly used semi-
quantitative metric for analysis of PET/CT oncology studies. The SUV represents 
the 18F-FDG uptake within a region of interest, normalized to both the injected 
dose and a factor that takes into account distribution throughout the body (such 
as body weight, lean body mass, or body surface area)6.7 . The SUV is influenced 
by many technical and physiologic factors including uptake time, body 
composition and blood glucose level8. Taken together, these factors can cause 
considerable variability in SUV measurements. In the past, knowledge of this 
variability has lead some to refer to the SUV as a "silly useless value"9. Recent 
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efforts to standardize quantitative PET imaging include recommendations and 
guidelines to minimize variability in the SUV and improve the reliability of results 
across different institutions 10-12 . 
One means of reducing SUV variability is by correcting lesion uptake to 
background uptake. A number of background sites have been used, including the 
liver, mediastinal blood pool and internal jugular vein (IJV). Recently, it was 
suggested that a 3-cm-diameter region of interest (ROI) on the right lobe of the 
liver be used for background correction in quantitative PET13. Liver SUV is stable 
over time 14 and more practical to measure than multiple levels of the aorta. 
Furthermore, uptake in the aorta may be influenced by atherosclerotic disease 15 . 
To date, no studies have directly compared sites of background correction for a 
variety of cancers . 
The purpose of this study was to determine whether liver FOG uptake can 
be used as a standard for background correction in PET/CT studies. Liver SUV 
values were compared to both mediastinal blood pool and IJV SUV values in 
cancers of the lung , breast, and head and neck. 
Materials and Methods 
Patients 
Institutional review board approval was obtained for this Health Insurance 
Portability and Accountability Act-compliant observational study with prospective 
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review of PET/CT images from our institutional electronic archival system; 
informed consent requirements were waived. The names of patients in whom 
new diagnoses of lung, breast and head and neck tumors were made between 
January 2008 and May 2009 at our institution were selected from our institutional 
tumor registry. A total of 145 patients with diagnoses of lung, breast and head 
and neck cancers who had undergone a baseline PET/CT study at our institution 
were identified from the tumor registry. The 145 patients (mean age, 59.1 years; 
age range, 26-91 years) consist of 57 (39.3%) men (mean age, 61.1 years; age 
range, 32-89 years) and 88 (60.7%) women (mean age, 57.9 years; age range 
26-91 years). 
PETICT Studies 
All PET/CT studies were performed (Discovery STE 16; General Electric, 
Milwaukee, Wis) according to the institutional standard clinical protocol. Weight, 
height, and blood glucose levels were recorded for all patients. Patients had a 
blood glucose level of 103.5 ± 25.5 mg/dl, were injected with 13.1 ± 2.9 mCi of 
18F-FDG, and scanned 77.5 ± 17.5 minutes post-injection . The amount of 
injected radioactivity was routinely measured by means of quantitation of the 
radioactivity of the syringe before and after injection. 
The dedicated head and neck imaging protocol consisted of 20 PET scan 
obtained from skull base to arch of the aorta with 30 em Field of View (FOV) and 
128 x 128 matrix. The emission scan lasted for 5 minutes per bed position. The 
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remainder of the body (down to the mid thighs) was imaged using a weight based 
emission scan time per bed position. PET slice thickness was 3.27 mm. Helical 
(16 detector) CT images were obtained with a matrix of 512 x 512 . Beam 
collimation was 1 Omm with a pitch of 0.984. Table speed was 9.84 mm/rotation 
and the slice thickness was 0.625mm. KV of 120 and mAs of 440 were used. 
When intravenous contrast (IV) was used, 60ml of Optiray IV (Tyco Health care I 
Mallinckrodt, Hezelwood) with a 30m I saline chaser was injected using a power 
injector (GE electric, Milwaukee) at 3ml/sec. CT images were reconstructed 
using a slice thickness of 3. 75mm every 3.27mm. In addition CT images were 
also reconstructed using a slice thickness of 1.25mm every 1.25mm in soft tissue 
and bone algorithm to generate a diagnostic level CT of the neck for review. 
Trunk (clavicle to mid thigh) PET scans were done using 30 imaging with 
emission scans that ranged from 2-4 minutes with a FOV of 50cm. The CT scans 
were obtained to match the PET scans' FOV and slice thickness. Two types of 
CT scans were done: a) Low dose scans for only attenuation correction and 
lesion localization of the PET data, or b) High dose scans for attenuation 
correction , lesion localization , and diagnostic level CT scan review. Both scans 
were done using a 512x512 matrix. The low dose scans were done without 
intravenous contrast. The pitch was approximately 1.75 and collimation was 
10mm. Slices were reconstructed at 3.75mm thickness and with a 3.27mm 
spacing . The x-ray beam was set at 120 kV and the mAs was modulated with a 
maximum set at 150. The high dose scans of the trunk included the use of oral 
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and intravenous contrasts. A total of 1 OOcc of Optiray 320 (Tyco Health care, 
Hazelwood) was given by intravenous injection at a rate of 3cc/sec and followed 
by a saline chase of 30cc at the same rate. The smartprep (GE Healthcare, 
Milwaukee) was used to trigger imaging once the celiac trunk reached a density 
of 180-200 HU. For the high dose scans the beam collimation was 10mm and the 
pitch was 0.984 with a slice thickness of 0.625mm. The beam was set at a peak 
voltage of 120kVand the mAs was modulated using a Noise Index of 15.1 with 
minimum of 30mAs and maximum of 340mAs. 
Image Analysis 
All PET/CT studies were retrieved from the electronic archival system and 
then prospectively reviewed on a workstation (Advantage; General Electric) 
under the supervision of a radiologist with board certification in nuclear medicine 
(R.M.S. , 3 years of experience). PET, CT, and fused PET/CT images were 
reviewed in axial , coronal , and sagittal planes. For the purposes of this study, the 
relevant standardized uptake values (SUVs) for calculation and reporting were 
those for the average SUV (SUVmean) and the maximum SUV (SUVmax) within the 
primary gross tumor volume. These were determined by visually identifying the 
region or regions on the PET images that qualitatively appear to have the most 
intense FOG uptake and that correspond to a known tumor based on other data, 
typically the CT scan. For SUVmax and SUVmean determination , a region of 
interest (ROI) incorporating the gross tumor volume was identified and the 
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manufacturer's algorithm (General Electric) was used to calculate the SUVmax 
and SUVmean within this ROI. 
Statistical Analysis 
Office Excel 2008 equipped with StatPius 2009 software was used to 
enter the data into a spreadsheet and perform statistical analyses. Liver SUVmean, 
SUVmean ratio (SUV mean of primary tumor I SUVmean of liver and SUVmean of 
primary tumor I SUV mean of mediastinum and SUVmean of primary tumor I 
SUVmean of IJV), and corrected SUVmax values (SUVmax of primary tumor I 
SUVmean of liver and SUVmax of primary tumor I SUV mean of mediastinum 
and SUVmax of primary tumor I SUVmean of IJV) were compared to those of the 
mediastinum for the breast and lung patient group and to those of the IJV for the 
head and neck patient group, respectively. A linear regression analysis was 
performed to graphically assess the relationship between different sites of 
background uptake and Pearson's correlation coefficient (r) was calculated to 
determine the strength of the association. The two-sample t test was used to 
compare mean values with respect to incubation time and intravenous contrast. 
A two tail p value< 0.05 were considered statistically significant. We present 
summary statistics as mean and standard deviation for continuous variables, or 
frequency and percentage for categorical variables. We used the independent 
samples t-test and Pearson's chi-squared test for between-group comparisons of 
continuous and categorical demographic variables. 
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Results 
Patients 
Ninety-eight patients with a diagnosis of breast or lung carcinoma and 
forty-seven patients with a diagnosis of head and neck carcinoma were included 
in this study. The mean age± standard deviation at the time of the PET/CT exam 
was 58.80 ± 14.11 years (range, 26-91 years) for the lung and breast patient 
group and 59.81 ± 10.63 years (range, 26-86 years) for the head and neck 
patient group. Of the patients in the lung and breast cancer group, twenty-five 
were male (mean age 63.76 ± 11.81 years ; age range 32-89 years) and seventy-
three were female (mean age 57.10 ± 14.50 years; age range 26-91 years) . Of 
the patients in the head and neck cancer group, thirty-two were male (mean age 
58.94 ± 7.52 years; age range 47-76) and fifteen were female (mean age 61 .67 ± 
15.50 years; age range 26-86). The patient characteristics for age and gender 
are summarized in table 1. 
SUV Measurements 
The average mediastinum and liver SUV values for the breast and lung 
cancer patient group were calculated . The average mediastinum SUVmean was 
1.33 ± 0.40 and the average liver SUVmean was 1.85 ± 0.51 . Average primary 
tumor SUVmean corrected for the mediastinal and liver background uptake were 
3.95 ± 2.47 and 2.85 ± 1.88, respectively. Average primary tumor SUVmax 
corrected for mediastinal and liver background uptake were 5.65 ± 3.64 and 4.09 
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± 2.81 , respectively. Similarly, average IJV and liver SUV vales for the head and 
neck cancer patient group were also calculated . The average IJV SUVmean was 
1.25 ± 0.37 and the average liver SUVmean was 1.83 ± 0.47. Average primary 
tumor SUVmean corrected for IJV and liver background uptake were 8.01 ± 4.38 
and 5.37 ± 2.77, respectively. Average primary tumor SUVmax corrected for 
mediastinal and liver background uptake were 10.35 ± 5.84 and 6.92 ± 3.64, 
respectively. The mean SUV values for both patient groups are summarized in 
table 2. 
Correlation Between Background Sites 
In the lung and breast cancer patient group, there was a positive 
correlation between liver SUVmean and mediastinum SUVmean (r = 0.89) , primary 
tumor SUVmean corrected for liver and mediastinal background uptake (r = 0.97) , 
and primary tumor SUVmax corrected for liver and mediastinal background uptake 
(r = 0.98) (Figure 1 ). The head and neck cancer patient group demonstrated a 
positive correlation between liver SUVmean and IJV SUVmean (r = 0.62) , primary 
tumor SUVmean corrected for IJV and liver background uptake (r = 0.89) , and 
primary tumor SUVmax corrected for IJV and liver background uptake (r = 0.90) 
(Figure 2). 
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Influence of Incubation period on SUV 
In the lung and breast cancer patient group, there was no significant 
difference in average mediastinum SUVmean between patient studies with 
incubation times less than or equal to seventy minutes (1.35 ± 0.41 , n = 47) and 
those with incubation times greater than seventy minutes (1 .32 ± 0.39, n = 51) (t 
= 0.39, p = 0.70). There was also no significant difference in average liver 
SUVmean between patient studies with incubation times less than or equal to 
seventy minutes (1 .85 ± 0.53, n = 47) and those with incubation times greater 
than seventy minutes (1 .85 ± 0.50, n = 51) (t = 0.04, p = 0.97) . The head and 
neck patient group demonstrated no significant difference in average IJV 
SUVmean between patient studies with incubation times less than or equal to 
seventy minutes (1 .31 ± 0.41 , n = 28) and those with incubation times greater 
than seventy minutes (1 .16 ± 0.29, n = 19) (t = 1.40, p = 0.17). There was also no 
significant difference in average liver SUVmean between patient studies with 
incubation times less than or equal to seventy minutes (1.94 ± 0.48, n = 28) and 
those with incubation times greater than seventy minutes (1.67 ± 0.42 , n = 19) (t 
= 2.02, p = 0.05) (Figure 3). 
Influence of IV Contrast on SUV 
In the lung and breast cancer patient group, there was no significant 
difference in average mediastinum SUVmean between patient studies with the use 
of intravenous contrast (1.32 ± 0.37, n = 41) and those without the use of 
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intravenous contrast (1.34 ± 0.43, n =57) (t = 0.22, p = 0.83) . There was also no 
significant difference in average liver SUVmean between patient studies with the 
use of intravenous contrast (1 .88 ± 0.52, n = 41) and those without the use of 
intravenous contrast (1 .83 ± 0.51 , n =57) (t = 0.49, p = 0.63) . The head and neck 
patient group demonstrated no sign ificant difference in average IJV SUVmean 
between patient studies with the use of intravenous contrast (1.21 ± 0.35, n = 32) 
and those without the use of intravenous contrast (1 .33 ± 0.41 , n = 15) (t = 1.07, 
p = 0.29). There was also no significant difference in average liver SUVmean 
between patient studies with the use of intravenous contrast (1 .79 ± 0.47, n = 32) 
and those without the use of intravenous contrast (1 .91 ± 0.48, n = 15) (t = 0.81 , 
p = 0.42) (Figure 4) . 
Discussion 
In quantitative PET/CT, the use of normal tissues as background is an 
important quality control. A recently published guideline has recommended the 
use of normal liver SUVmean as background because it is both reliable and easy 
to measure 13 . However, to the best of our knowledge, there are no existing 
studies that have compared different background sites for a number of cancers. 
In this study, we examined the relationship between the liver and two other sites 
commonly used for background normalization, the mediastinal blood pool and 
internal jugular vein (representing the neck blood pool). 
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In patients with primary carcinoma of the lung and breast, a strong positive 
correlation was observed between liver SUVmean values and SUVmean values for 
the mediastinal blood pool. This finding suggests that normal liver may be 
comparable to the mediastinum for background normalization in cancers of the 
lung or breast. In head and neck cancer patients, the correlation between liver 
and IJV SUVmean values was positive, although weaker than the correlation 
between the liver and mediastinum SUVmean· We believe this result is likely due 
to the difference in protocols for head and neck versus lung and breast scans. In 
protocols for the head and neck, body parts from mid thigh to clavicle are 
scanned cauda-cranial direction before the patient is repositioned for imaging 
from the skull base to arch of the aorta with a higher matrix and larger field of 
view. Therefore, the difference in uptake time will be greater between the IJV and 
the liver than it will be for the liver and mediastinal blood pool. In addition , the 
matrix and field of view are greater for scans of the head and neck where the 
background SUVmean for IJV was measured. This would have likely increased the 
SUVmean for IJV artifactuallyB. These factors are reflected in the weaker 
correlation between background SUVmean values of the IJV and liver. 
The influence of uptake time and the use of IV contrast on the SUV were 
evaluated for both patient groups. It is well known that the SUV tends to increase 
with greater time post-injection . In one study that compared normal tissues at 1 
and 3 hours post-injection , significant changes (as much as 13%) were observed 
in the mean SUV of the aortic blood pool , whereas no significant changes were 
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observed in the mean SUV of the liver16 . In our study, there was no significant 
difference in the SUVmean of the liver, mediastinum or IJV when an incubation 
time cutoff of 70 minutes was used. An incubation time of 70 minutes is 
consistent with both European and North American guidelines for PET/CT 
protocol13•17. 
The use of IV contrast is also known to affect the SUV. Differences in SUV 
values between PET/CT studies with contrast and those without contrast have 
been shown to be as large as 5.9%.18 In our study the IV contrast was not found 
to significantly influence the SUVmean of the liver, mediastinum or IJV. However, 
our result may be limited by the study design of comparing two independent 
cohorts of patients who did or did not receive contrast. In studies that have found 
the affect of IV contrast on the SUV to be significant, a test-retest approach has 
typically been used19 . If our sample size was large enough , the variation 
between two independent groups would be reduced and our approach would be 
similar to using a single group with a test-retest hypothesis. 
Our findings suggest that normal liver SUVmean may be a suitable 
background for standardizing PET/CT oncology studies of lung , breast and head 
and neck patients. In patients having undergone a PET/CT for primary diagnosis 
or initial staging of lung or breast carcinoma, liver SUVmean correlated strongly 
with mediastinum SUVmean· Liver SUVmean also correlated with IJV SUVmean in 
patients having undergone a PET/CT for primary diagnosis or initial staging of 
head and neck carcinoma, although this association was less strong. The liver 
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SUVmean was not significantly affected by differences in incubation time or the 
use of IV contrast for either patient group. 
Recently published abstracts have suggested that the SUV is a reliable 
internal reference in patients with benign liver disease20 , is independent of both 
age and gende~1 , and may be a reliable site for background comparison before 
and after chemotherapl2 . One imitation of using liver SUVmean as background 
may be in patients where the liver is diseased. In patients with metastatic liver 
disease, it is often difficult to differentiate lesion uptake from normal physiologic 
uptake (Figure 5) . In a recent study by Abele and Fung that examined benign 
disease in the liver, hepatic steatosis was shown to not significantly affect the 
mean SUV of the live~3 . However, more studies of are clearly needed before the 
liver is considered the standard background comparator in PET/CT oncology 
studies. 
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Tables and Figures 
Table 1: Baseline characteristics of study patients and tumor types 
Female 57.10 ± 14.50 61 .67 ± 15.50 
Male 63.76 ± 11.81 58.94 ± 7.52 
All Patients 58.80 ± 14.11 59.81 ± 10.63 
Sex 
Female 73 15 
Male 25 32 
* Data are mean ± standard deviation 
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Table 2: SUV characteristics of study population 
Mediastinum Liver IJV Liver 
SUVmean 
Mean 1.33 1.85 1.25 1.83 
Std Dev 0.40 0.51 0.37 0.47 
Range 0.6-2.4 0.8-3.2 0.6-2.3 1-3.1 
Primary Tumor 
Corrected SUV mean 
Mean 3.95 2.85 8.01 5.37 
Std Dev 2.47 1.88 4.38 2.77 
Range 0.41-11 .33 0.30-9.81 2.06-18 1.30-14.54 
Primary Tumor 
Corrected SUV max 
Mean 5.65 4.09 10.35 6.92 
Std Dev 3.64 2.81 5.84 3.64 
Range 0.39-17.13 0.39-17.13 2.43-25 1.7-16.07 
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Figure 1. Liver uptake versus mediastinum uptake in lung and breast cancer 
patients using (a) SUVmean, (b) Primary tumor corrected SUVmean. and (c) Primary 
tumor corrected SUVmax- There is significant correlation between (a) liver 
SUVmean and mediastinum SUVmean (r = 0.89, p < 0.0001 ), (b) liver SUVmean ratio 
and mediastinum SUVmean ratio (r = 0.97, p < 0.0001 ), and (c) liver corrected 
SUVmax and mediastinum corrected SUVmax (r = 0.98, p < 0.0001 ). 
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Figure 2. Liver uptake versus IJV uptake in head and neck cancer patients using 
(a) SUVmean. (b) Primary tumor corrected SUVmean, and (c) Primary tumor 
corrected SUVmax· There is significant correlation between (a) liver SUVmean and 
IJV SUVmean (r = 0.62, p < 0.0001), (b) liver SUVmean ratio and IJV SUVmean ratio 
(r = 0.89, p < 0.0001 ), and (c) liver corrected SUVmax and IJV corrected SUVmax (r 
= 0.90, p < 0.0001). 
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Figure 3. SUVmean values and incubation time above and below 70 min for breast 
and lung cancer patients (a and b) and head and neck cancer patients (c and d). 
For lung and breast patients, the mediastinum SUVmean was 1.35 ± 0.41 (~ 70 
min) and 1.32 ± 0.39 (> 70 min) (p = 0. 70) ; the liver SUVmean was 1.86 ± 0.53 (~ 
70 min) and 1.85 ± 0.50 (> 70 min) (p = 0.97) . For head and neck patients, the 
IJV SUVmean was 1.31 ± 0.41 (~ 70 min) and 1.16 ± 0.29 (> 70 min) (p = 0.17); 
the liver SUVmean was 1.94 ± 0.48 (~ 70 min) and 1.67 ± 0.42 (> 70 min) (p = 
0.05). 
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Figure 4. SUVmean values with and without the use of IV contrast for breast and 
lung cancer patients (a and b) and head and neck cancer patients (c and d). For 
lung and breast patients, the mediastinum SUVmean was 1.32 ± 0.37 (with 
contrast) and 1.34 ± 0.43 (without contrast) (p = 0.83); the liver SUVmean was 1.88 
± 0.52 (with contrast) and 1.83 ± 0.51 (without contrast) (p = 0.63). For head and 
neck patients, the IJV SUVmean was 1.21 ± 0.35 (with contrast) and 1.33 ± 0.41 
(without contrast) (p = 0.29); the liver SUVmean was 1.79 ± 0.47 (with contrast) 
and 1.91 ± 0.48 (without contrast) (p = 0.42). 
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Figure 5. CT and fused PET/CT images of the abdomen. There are numerous 
hepatic metastases, which will increase the background liver uptake. In these 
circumstances, liver background uptake cannot be used for background 
correction. 
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